Concanamycin A
V-ATPase inhibitor / A potent and specific inhibitor of the vacuolar (V-type) H+-ATPase which can induce apoptotic cell death in various cell lines.1,2 Inhibits cell surface expression of virus envelope glycoproteins.3 Dramatically increases the rate of extracellular vesicle release from a variety of cell types.4 Inhibits autophagy by blocking lysosomal acidification.5
Biochemicals & reagents
80890-47-7
Folimycin
1) Nishihara et al. (1995), Specific inhibitors if vacuolar type H(+)-ATPases induce apoptotic cell death; Biochem. Biophys, Res. Commun., 212 255 2) Hong et al. (2006), Nitric oxide production by the vacuolar-type (H+)-ATPase inhibitors bafilomycin A1 and concanamycin A and its possible role in apoptosis in RAW 264.7 cells; J. Pharmacol. Exp. Ther., 319 672 3) Muroi et al. (1993), Folimycin (concanamycin A), a specific inhibitor of V-ATPase, blocks intracellular translocation of the glycoprotein of vesicular stomatitis virus before arrival to the Golgi appparatus; Cell Struct. Function, 18 139 4) Cashikar and Hanson (1987), A cell-based assay for CD63-containing extracellular vesicles; PLoS One, 14 e0220007 5) Gradzka et al. (2018), Inhibitor of apoptosis proteins are required for effective fusion of autophagosomes with lysosomes; Cell Death Dis., 9 529
-20°C
TARGET: ATPase; Antibiotic -- PATHWAY: Protein synthesis; Autophagy -- RESEARCH AREA: Cell death -- DISEASE AREA: Infectious disease